← back to search

Olga Sagalova

Ural State Medical University · RU
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and Hepatitis Viruses Studies and Epidemiology.
h-index
17
citations
4,262
works
90
NIH funding
primary concept
email

Recent publications

Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
New England Journal of Medicine 2024cited by 76position: middledoi
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Journal of Hepatology 2024cited by 66position: middledoi
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
Journal of Hepatology 2024cited by 19position: middledoi
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
New England Journal of Medicine 2023cited by 207position: middledoi
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
The Lancet Infectious Diseases 2022cited by 154position: middledoi
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Journal of Hepatology 2022cited by 32position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John F. Flaherty · University of California, San Francisco2 papers (2022–2024)Heiner Wedemeyer · Ruhr University Bochum2 papers (2022–2024)Pietro Lampertico · Pitié-Salpêtrière Hospital2 papers (2022–2024)Vladimir Chulanov · Institute of Parasitology2 papers (2022–2024)Anu Osinusi · Gilead Sciences (United States)2 papers (2022–2024)Vithika Suri · Evorx (United States)2 papers (2022–2024)Soo Aleman · Development Fund2 papers (2022–2024) · 1 papers (2022–2022)Natalia Geyvandova · Stavropol Regional Clinical Oncology Center1 papers (2022–2022)Marı́a Buti · Second Affiliated Hospital of Xi'an Jiaotong University1 papers (2024–2024) · 1 papers (2024–2024)Ankita Kaushik · Gilead Sciences (United States)1 papers (2024–2024)Pietro Andreoné · University of Modena and Reggio Emilia1 papers (2022–2022)Maurizia Rossana Brunetto · University of Pisa1 papers (2022–2022)Qi An · Hokkaido University of Science1 papers (2022–2022)Viacheslav Morozov · Pitié-Salpêtrière Hospital1 papers (2024–2024)Andrew R. Lloyd · UNSW Sydney1 papers (2024–2024)Markus Cornberg · Technische Universität Braunschweig1 papers (2022–2022)Dmitry Manuilov · Gilead Sciences (United States)1 papers (2022–2022)Julian Schulze zur Wiesch · Universität Hamburg1 papers (2022–2022)